OpenEvidence announced a collaboration with the American College of Rheumatology on November 6, 2026, bringing ACR’s patient education fact sheets into its medical AI platform. The announcement came at ACR Convergence 2026 and focuses on a practical part of care: helping clinicians give patients and caregivers clear information during an appointment.
The English- and Spanish-language resources will appear alongside peer-reviewed medical literature when they are clinically relevant. Each fact sheet includes a link back to the original ACR resource, so clinicians can use patient-friendly explanations without losing access to the source material.
Turning clinical information into a shared conversation
The collaboration serves rheumatologists, primary care physicians and other specialists who treat people with rheumatic conditions. That reach matters because care for rheumatic disease does not stay inside rheumatology practices. Many conditions are chronic and complex, and patients and caregivers may manage them for years with help from several healthcare professionals.
ACR represents more than 10,600 rheumatology professionals worldwide. Its fact sheet collection covers diseases, conditions and treatments, including gout, psoriatic arthritis, nonsteroidal anti-inflammatory drugs and biologic medications.
The pages use accessible language to explain causes, common signs and symptoms, diagnosis and treatment. They also identify topics that patients and caregivers can discuss with healthcare providers as they prepare questions about a diagnosis or treatment plan. Clinicians can use the material to reinforce those conversations and help people feel more prepared to participate in their care.
ACR president William Harvey, MD, MSc, FACR, said, “Patients and caregivers need information they can understand, trust, and return to after an appointment.” The OpenEvidence workflow is designed around that need by placing patient-oriented explanations and clinical literature in the same place.
What patients and caregivers will find
ACR treatment pages describe how common medications and therapies work, common dosages, safety tips, possible side effects and risks. Spanish versions are available for most treatment pages, and English pages link to their Spanish counterparts.
The gout and psoriatic arthritis fact sheets show how ACR maintains the material. Both offer print-or-save-as-PDF options and links to Spanish versions. Each carries a February 2025 update credit: Pankti Reid, MD, MPH, for gout and Kiren Sahni, MD, for psoriatic arthritis. ACR’s communications and marketing committee reviewed both updates.
ACR labels the disease and treatment information as general education only. It directs individuals to qualified healthcare professionals for advice, diagnosis and treatment of their own conditions. That boundary remains important as more people use digital tools to look for health information before or between appointments.
More than 53 million U.S. adults have been diagnosed with arthritis. Clear, consistent material can help patients and caregivers understand a diagnosis, follow a treatment plan and know what to ask their healthcare teams.
Why the guardrails around medical AI matter
Everyone is trying to forecast AI’s effects on healthcare. Some believe it will free medical professionals from mundane administrative tasks so they can spend more time with patients. Others worry that AI will erode the hands-on expertise needed for comprehensive, compassionate care.
Dr. Paige Kilian, Chief Medical Officer at Inovalon, has described the risk of physicians losing opportunities to learn by experience as AI creates an easy path to diagnosis. The concern is that overreliance on technology could come at the expense of patient outcomes. One statement captures the point: “Autopilot could not have landed Captain Sully’s plane.”
Other findings show why medical AI needs careful limits. Research cited in a cutaneous lupus erythematosus article found that approximately one-third of patients diagnosed with CLE without systemic involvement had moderate-to-high disease activity at their most recent specialty visit, despite prescription treatment. The findings underscored limits in current treatment approaches as late-stage therapies moved toward possible approval.
Separate testing at Vals AI examined how 17 current AI chatbots responded to teenagers across more than 30,000 simulated conversations. Medication came up in more than 5,500 conversations, and chatbots made a medication decision for the teen 22 percent of the time. Telling the chatbot it was speaking to a teen reduced that figure to 8 percent, but not to zero.
The systems varied widely. OpenAI’s newest model and Meta’s Muse Spark almost never made those decisions, while others did so in about two out of three cases. When a teen pushed back after a chatbot refused to advise them, failures rose from 15 percent to 25 percent. The conversations ran for up to 20 exchanges, and real conversations can stretch across days and many sessions.
About 1 in 4 U.S. adults now use AI tools for health information, while nearly 1 in 5 U.S. teens and young adults have used AI chatbots for mental health advice. People turn to these tools because they are always available and easy to reach. As one teen put it, “AI is like a machine that knows more than Google.”
That makes the OpenEvidence and ACR collaboration different from a chatbot offering unsupervised medical advice. The fact sheets surface when clinically relevant, sit beside peer-reviewed literature and preserve a link to the original ACR resource. They support a conversation between patients and healthcare professionals rather than replacing it.
The broader lesson is simple: medical AI works best when it connects people with dependable information and qualified care. ACR’s resources give clinicians a consistent way to explain rheumatic conditions and treatments, while their warnings remind patients that education is not a diagnosis or a personal treatment plan.
Based on
- OpenEvidence Adds ACR Patient Fact Sheets to Clinical AI Workflow — unite.ai
- How Healthcare AI’s Early Wins Can Have A Lasting Impact — forbes.com
- One in Three Treated Patients with Cutaneous Lupus Without Systemic Involvement Have Moderate-to-High Disease Activity, Spherix Global Insights Finds | Markets Insider — markets.businessinsider.com
- AI chatbots are giving medication advice, and some of it is deadly — thehill.com
